Skip to content
Parakho

Rossari Biotech Ltd

NSE ROSSARIBSE 543213rossari.com

Q1 FY27, unaudited

Revenue
₹697.20 Cr
Profit after tax
₹35.10 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations697.20+28.23%2,396.37
Other income3.19+165.58%22.38
Total income700.39+28.53%2,418.74
Employee benefit expense44.04+17.56%154.75
Finance costs10.98+91.64%28.54
Depreciation & amortisation25.62+44.32%79.12
Total expenses653.17+30.81%2,218.13
Profit before tax47.22+3.59%200.61
Tax expense12.58+0.59%53.30
Profit after tax35.10+4.46%149.21
Total comprehensive income35.45+5.84%149.29
Earnings per share
Earnings per share, basic₹6.34₹26.95
Earnings per share, diluted₹6.33₹26.93

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Earnings call

Q1 FY27

Rossari Biotech reported consolidated revenue of Rs. 697.2 crore in Q1 FY27, up 28% YoY, along with its highest ever quarterly EBITDA of Rs. 80.6 crore, up 18.7% YoY, though EBITDA margin declined to 11.6% from 12.5% a year earlier. Management attributed the margin pressure to the institutional and consumer business, raw material and freight volatility, and product mix, while noting that core B2B operations excluding these businesses delivered around 14% EBITDA margin. The company discussed ongoing initiatives including a new Thailand blending plant, a proposed Saudi Arabia project, a new Fibre Chemicals Division, and continued monetization of non-core assets such as the Andheri office.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 53 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 06 Aug 2026.